Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DAO | P14920 | 1/20 | 0.33 |
| ▸ | TSHR | P16473 | 1/20 | 0.33 |
| ▸ | MAPT | P10636 | 2/20 | 0.31 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.31 |
| ▸ | MEN1 | O00255 | 1/20 | 0.31 |
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.31 |
| ▸ | HSP90AB1 | P08238 | 1/20 | 0.31 |
| ▸ | HPGD | P15428 | 1/20 | 0.31 |
| ▸ | HTT | P42858 | 1/20 | 0.31 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.31 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15542445 | 0.78 | TSHR (0.37) | TSHRMAPTKDM4EMEN1HSP90AA1 | |
| SCHEMBL30845424 | 0.76 | ASPH (0.35) | TSHRMAPTKDM4EHPGD | |
| SCHEMBL9930640 | 0.76 | PKM (0.38) | TSHRMAPTKDM4EHPGDKMT2A | |
| SCHEMBL2235253 | 0.76 | LMNA (0.37) | DAOTSHRMAPTALDH1A1 | |
| SCHEMBL1492106 | 0.76 | CSF1R (0.42) | — | |
| SCHEMBL9930898 | 0.75 | LPAR1 (0.35) | MAPTKDM4EALDH1A1 | |
| SCHEMBL9930841 | 0.72 | YTHDC1 (0.35) | TSHRMAPTALDH1A1 | |
| SCHEMBL18633737 | 0.72 | ALDH1A1 (0.33) | TSHRMAPTKDM4EALDH1A1 | |
| SCHEMBL9931007 | 0.72 | GABRP (0.37) | DAOTSHRMAPTALDH1A1 | |
| SCHEMBL2235201 | 0.72 | ALDH1A1 (0.40) | TSHRMAPTALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120157439-A1 | RAF INHIBITOR COMPOUNDS AND METHODS OF USE THEREOF | GENENTECH, INC. (US) | 2012-06-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120157439-A1 | RAF INHIBITOR COMPOUNDS AND METHODS OF USE THEREOF | BRAF, RAF1, ARAF | DAO 2437/4885TSHR 2668/4885MAPT 1082/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.